S299 Yield of Post-Polypectomy Interval Fecal Immunochemical Testing: Results From a Large Nationwide Veterans’ Affairs Database
Introduction: Current guidelines recommend surveillance colonoscopy after polypectomy. In real-world practice, fecal immunochemical testing (FIT) is sometimes used for surveillance after polypectomy, though little data exists to inform its use in this setting. This study aims to evaluate the yield of interval FIT (iFIT) in patients with prior polypectomy compared to those without polypectomy, focusing on 1) the impact of polypectomy on iFIT results, 2) adherence to follow-up colonoscopy after a positive iFIT, and 3) to determine whether polypectomy is a predictor of advanced colorectal neoplasia (ACRN) or colorectal cancer (CRC) after positive iFIT. Methods: We analyzed data from the Veterans Health Administration Corporate Data Warehouse from 2000-2024. Patients who underwent colonoscopy for any indication followed by iFIT within 10 years and before another colonoscopy were included. Advanced colorectal neoplasia (ACRN) was defined as adenoma with high-grade dysplasia (HGD), tubulovillous (TVA), or CRC. Results: Overall, 4,799,644 individuals underwent colonoscopy and 10.9% (525,157) had iFIT. Of these, 49.9% underwent polypectomy at index colonoscopy. The average time from index colonoscopy to iFIT was 5.9 years. iFIT was positive in 17.2% (44,931) of post-polypectomy patients vs 14.1% (37,081) without polypectomy. History of polypectomy was an independent predictor of positive iFIT (odds ratio [OR] 1.12; 95% confidence interval [CI], 1.10–1.15; P < 0.0001). Follow-up colonoscopy after positive iFIT was performed in 50.4% of post-polypectomy patients and 49.3% without polypectomy. Findings on follow-up colonoscopy in those with and without polypectomy were as follows: tubular adenoma (54.7% vs 45.8%), TVA (5.6% vs 4.7%), adenoma with HGD (0.82% vs 0.66%), sessile serrated lesion (3.52% vs 2.42%), ACRN (9.2% vs 7.9%), and CRC (3.3% vs 3.0%), respectively. Prior polypectomy was not an independent predictor of CRC (OR 0.96; 95% CI, 0.82–1.13; P = 0.65) or ACRN (OR 0.97; 95% CI, 0.88–1.07; P = 0.57) at colonoscopy post-iFIT. Conclusion: In this large U.S. cohort, iFIT was performed frequently in patients with and without polypectomy at index colonoscopy, and was positive in 14%-17%. Colonoscopy after positive iFIT revealed high rates of ACRN and CRC, irrespective of polypectomy history. These findings reinforce the importance of colonoscopy following positive iFIT given the high risk of ACRN and CRC, regardless of polypectomy history.
Authors
- Aasma Shaukat (ORCID: https://orcid.org/0000-0003-2446-8858)
- Amy Gravely (ORCID: https://orcid.org/0000-0003-3030-6935)
- Anders Westanmo (ORCID: https://orcid.org/0000-0003-4722-1663)
- Natalie Wilson (ORCID: https://orcid.org/0000-0003-1648-3310)
- Mohammad Bilal (ORCID: https://orcid.org/0000-0002-1784-212X)
- Khalid Ishani (ORCID: https://orcid.org/0000-0003-1579-191X)
- Rahul Karna
Publication Details
- Journal
- The American Journal of Gastroenterology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.14309/01.ajg.0001128656.05337.41
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00